Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGMO

Sangamo Therapeutics Inc

Nov 15 • 04:00PM ET

2.05

Dollar change -0.10
Percentage change -4.65	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP NTLA BMRN EDIT QURE BLUE FGEN VYGR VXRT

| Held by: VTI VXF SCHA FESM GNOM VHT PRFZ SCHB QQQS AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	4.60%	Shs Outstand	208.65M	Perf Week	-28.57%
Market Cap	407.84M	Forward P/E	-	EPS next Y	-0.09	Insider Trans	0.00%	Shs Float	199.04M	Perf Month	119.09%
Income	-136.13M	PEG	-	EPS next Q	-0.09	Inst Own	26.91%	Short Float	9.54%	Perf Quarter	137.82%
Sales	52.29M	P/S	7.80	EPS this Y	66.60%	Inst Trans	-19.91%	Short Ratio	2.64	Perf Half Y	215.58%
Book/sh	0.19	P/B	10.93	EPS next Y	80.92%	ROA	-82.26%	Short Interest	18.98M	Perf Year	461.34%
Cash/sh	0.20	P/C	10.40	EPS next 5Y	-	ROE	-156.42%	52W Range	0.30 - 3.18	Perf YTD	277.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.96%	ROI	-203.60%	52W High	-35.51%	Beta	1.12
Dividend TTM	-	Quick Ratio	1.35	Sales past 5Y	17.84%	Gross Margin	80.48%	52W Low	574.34%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	1.35	EPS Y/Y TTM	48.16%	Oper. Margin	-256.68%	RSI (14)	54.18	Volatility	18.27% 21.03%
Employees	405	Debt/Eq	0.71	Sales Y/Y TTM	-74.04%	Profit Margin	-260.33%	Recom	2.00	Target Price	6.20
Option/Short	Yes / Yes	LT Debt/Eq	0.71	EPS Q/Q	107.45%	Payout	-	Rel Volume	0.92	Prev Close	2.15
Sales Surprise	136.17%	EPS Surprise	361.44%	Sales Q/Q	425.77%	Earnings	Nov 12 AMC	Avg Volume	7.19M	Price	2.05
SMA20	1.58%	SMA50	54.66%	SMA200	145.49%	Trades		Volume	6,578,882	Change	-4.65%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6 → $2
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform	$5 → $1.50
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform	$16
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $5
Jun-13-22	Resumed	Wedbush	Neutral	$5
May-04-21	Initiated	RBC Capital Mkts	Outperform	$22
Jan-07-21	Resumed	Guggenheim	Neutral	$16
Jan-06-21	Initiated	Stifel	Hold	$16
Dec-16-20	Resumed	H.C. Wainwright	Buy	$25
Sep-08-20	Initiated	BofA Securities	Buy	$20
Jul-07-20	Initiated	SunTrust	Buy	$22
Aug-26-19	Initiated	H.C. Wainwright	Buy	$16
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy	$24
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy	$17
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral	$30 → $4
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral

Show Previous Ratings

Nov-13-24 09:49AM	Q3 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -9.96%
02:16AM	Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 05:15PM	Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:09PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (Business Wire)
04:15PM	Loading…
Nov-04-24 04:15PM	Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (Business Wire) -7.45% +24.14%
Oct-23-24 07:45AM	Merck acquires cancer drug startup; Elevidys ex-US sales rise (BioPharma Dive) +27.27%
Oct-22-24 08:05AM	Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (Business Wire) +32.53%
Aug-07-24 01:24PM	Q2 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.46%
04:32AM	Genentech and Sangamo to develop neurodegenerative disease therapies (Pharmaceutical Technology)
Aug-06-24 05:35PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +28.95%
04:37PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (Business Wire)
08:11AM	Roche licenses Sangamos technology for another shot at Alzheimers drugs (BioPharma Dive)
08:05AM	Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases (Business Wire)
04:15PM	Loading…
Jul-30-24 04:15PM	Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (Business Wire) -23.64% +11.80%
Jul-24-24 06:55AM	Sangamo Therapeutics Reports on Pfizers Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate (Business Wire) +39.55%
May-12-24 08:28AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:58PM	Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights (GuruFocus.com) +7.26%
May-09-24 08:58PM	SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:25PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (Business Wire)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:05AM	Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing (Business Wire)
May-02-24 04:15PM	Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast (Business Wire) +6.48%
Apr-22-24 04:35PM	Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire)
Mar-22-24 08:05AM	Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering (Business Wire) -27.55%
Mar-14-24 07:23AM	Q4 2023 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:21AM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance) -8.83%
08:05AM	Loading…
08:05AM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
08:01AM	Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs (Business Wire)
Mar-12-24 06:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast (Business Wire)
Feb-12-24 08:05AM	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (Business Wire) +40.15%
Feb-05-24 06:01PM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile (Business Wire) +13.91% -7.02%
Nov-03-23 05:03PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:15AM	Sangamo to cut jobs again with planned business overhaul (BioPharma Dive) -22.14%
Nov-01-23 07:05PM	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update (GuruFocus.com) -6.25%
04:13PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 10:02AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 04:15PM	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Business Wire)
Oct-24-23 02:01AM	Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Sep-20-23 04:15PM	Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit (Business Wire)
Aug-25-23 01:38PM	Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases (InvestorPlace) -12.49%
Aug-08-23 05:30PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.89%
04:26PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:15PM	Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (Business Wire)
Jul-20-23 08:05AM	Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing (Business Wire)
Jul-19-23 07:08AM	The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable (Simply Wall St.)
Jul-17-23 08:05AM	Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids (Business Wire)
Jun-29-23 08:05AM	Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease (Business Wire)
Jun-28-23 09:20AM	FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing (Zacks)
Jun-14-23 08:16AM	We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate (Simply Wall St.)
May-22-23 08:05AM	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease (Business Wire) +5.43%
May-18-23 07:04AM	Industry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52% (Simply Wall St.)
May-16-23 08:00AM	Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer (Business Wire)
May-02-23 04:30PM	Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -9.27%
06:03AM	Analysts Just Made A Huge Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts (Simply Wall St.)
Apr-26-23 05:28PM	Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results (Business Wire)
Apr-25-23 02:39PM	Biogen shifts gene therapy focus as it builds $200M facility in RTP (American City Business Journals)
Apr-21-23 04:58AM	Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength? (Zacks)
Apr-19-23 04:15PM	Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast (Business Wire)
Apr-17-23 07:38AM	Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.45%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Mar-23-23 06:09AM	The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership (American City Business Journals)
Mar-21-23 09:35AM	Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-20-23 12:25PM	Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo (Benzinga)
Mar-10-23 09:35AM	Sangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-23 08:26AM	In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Feb-23-23 05:36PM	Sickle-cell gene therapy developer stops program, cuts half of staff (American City Business Journals) -9.08%
11:57AM	Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit (Benzinga)
Feb-22-23 05:25PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
03:01PM	Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease (Business Wire)
09:35AM	Here's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks (Zacks)
Feb-21-23 09:01AM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast (Business Wire) -7.49%
Feb-16-23 10:01AM	Sangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-13-23 09:55AM	Here's Why Sangamo (SGMO) Looks Ripe for Bottom Fishing (Zacks)
Feb-10-23 11:01AM	Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week (Motley Fool)
Jan-30-23 07:10PM	7 CRISPR Stocks With the Best Long-Term Potential (InvestorPlace) -5.03%
Dec-06-22 06:02AM	Sangamo Therapeutics (NASDAQ:SGMO) investors are sitting on a loss of 78% if they invested five years ago (Simply Wall St.)
Nov-09-22 05:31AM	Sangamo Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-03-22 05:55PM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -12.77%
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results (Business Wire)
Oct-27-22 04:15PM	Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast (Business Wire)
Oct-14-22 09:49AM	10 Best Gene Editing Stocks To Buy (Insider Monkey)
Oct-12-22 08:55AM	Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate (Benzinga)
03:01AM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients (Business Wire)
Sep-23-22 12:02PM	Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold (Benzinga)
Sep-18-22 09:11AM	Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Aug-30-22 08:50AM	Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile (Benzinga)
06:00AM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients (Business Wire)
Aug-29-22 09:55AM	Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 106% Upside in Sangamo (SGMO): Here's What You Should Know (Zacks) +8.76%
Aug-04-22 05:45PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.01%
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results (Business Wire)
Jul-28-22 04:15PM	Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast (Business Wire)
Jul-21-22 08:05AM	European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation (Business Wire)

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMO

Sangamo Therapeutics Inc

Upgrade your FINVIZ experience